470 related articles for article (PubMed ID: 31653838)
41. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations.
Jiang Y; Chen M; Nie H; Yuan Y
Hum Vaccin Immunother; 2019; 15(5):1111-1122. PubMed ID: 30888929
[TBL] [Abstract][Full Text] [Related]
42. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
43. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
44. Self-delivery photothermal-boosted-nanobike multi-overcoming immune escape by photothermal/chemical/immune synergistic therapy against HCC.
Yang H; Mu W; Yuan S; Yang H; Chang L; Sang X; Gao T; Liang S; Liu X; Fu S; Zhang Z; Liu Y; Zhang N
J Nanobiotechnology; 2024 Mar; 22(1):137. PubMed ID: 38553725
[TBL] [Abstract][Full Text] [Related]
45. Photothermally activatable PDA immune nanomedicine combined with PD-L1 checkpoint blockade for antimetastatic cancer photoimmunotherapy.
Lu Q; Qi S; Li P; Yang L; Yang S; Wang Y; Cheng Y; Song Y; Wang S; Tan F; Li N
J Mater Chem B; 2019 Apr; 7(15):2499-2511. PubMed ID: 32255127
[TBL] [Abstract][Full Text] [Related]
46. Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures.
Della Corte CM; Barra G; Ciaramella V; Di Liello R; Vicidomini G; Zappavigna S; Luce A; Abate M; Fiorelli A; Caraglia M; Santini M; Martinelli E; Troiani T; Ciardiello F; Morgillo F
J Exp Clin Cancer Res; 2019 Jun; 38(1):253. PubMed ID: 31196138
[TBL] [Abstract][Full Text] [Related]
47. Photothermally sensitive gold nanocage augments the antitumor efficiency of immune checkpoint blockade in immune "cold" tumors.
Xiao G; Zhao Y; Wang X; Zeng C; Luo F; Jing J
Front Immunol; 2023; 14():1279221. PubMed ID: 37942337
[TBL] [Abstract][Full Text] [Related]
48. Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition: impact on clinical outcome.
Araujo B de Lima V; Borch A; Hansen M; Draghi A; Spanggaard I; Rohrberg K; Reker Hadrup S; Lassen U; Svane IM
Cytotherapy; 2020 Apr; 22(4):204-213. PubMed ID: 32201034
[TBL] [Abstract][Full Text] [Related]
49. The role of exosomal PD-L1 in tumor progression and immunotherapy.
Xie F; Xu M; Lu J; Mao L; Wang S
Mol Cancer; 2019 Oct; 18(1):146. PubMed ID: 31647023
[TBL] [Abstract][Full Text] [Related]
50. ICG-labeled PD-L1-antagonistic affibody dimer for tumor imaging and enhancement of tumor photothermal-immunotherapy.
Jia D; Zhao S; Liu H; Zhan X; Zhou Z; Lv M; Tang X; Guo W; Li H; Sun L; Zhong Y; Tian B; Yuan D; Tang X; Fan Q
Int J Biol Macromol; 2024 Jun; 269(Pt 2):132058. PubMed ID: 38704065
[TBL] [Abstract][Full Text] [Related]
51. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
52. IFN-γ Promotes Epithelial-Mesenchymal Transition and the Expression of PD-L1 in Pancreatic Cancer.
Imai D; Yoshizumi T; Okano S; Itoh S; Ikegami T; Harada N; Aishima S; Oda Y; Maehara Y
J Surg Res; 2019 Aug; 240():115-123. PubMed ID: 30927618
[TBL] [Abstract][Full Text] [Related]
53. The helminth-derived peptide GK-1 induces an anti-tumoral CD8 T cell response associated with downregulation of the PD-1/PD-L1 pathway.
Rodríguez-Rodríguez N; Madera-Salcedo IK; Bugarin-Estrada E; Sánchez-Miranda E; Torres-García D; Cervantes-Torres J; Fragoso G; Rosetti F; Crispín JC; Sciutto E
Clin Immunol; 2020 Mar; 212():108240. PubMed ID: 31299381
[TBL] [Abstract][Full Text] [Related]
54. Reprogramming the Tumor Microenvironment through Second-Near-Infrared-Window Photothermal Genome Editing of PD-L1 Mediated by Supramolecular Gold Nanorods for Enhanced Cancer Immunotherapy.
Tang H; Xu X; Chen Y; Xin H; Wan T; Li B; Pan H; Li D; Ping Y
Adv Mater; 2021 Mar; 33(12):e2006003. PubMed ID: 33538047
[TBL] [Abstract][Full Text] [Related]
55. Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer.
Kurozumi S; Fujii T; Matsumoto H; Inoue K; Kurosumi M; Horiguchi J; Kuwano H
Med Mol Morphol; 2017 Dec; 50(4):185-194. PubMed ID: 28936553
[TBL] [Abstract][Full Text] [Related]
56. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
[TBL] [Abstract][Full Text] [Related]
57. Selectively down-regulated PD-L1 by albumin-phenformin nanoparticles mediated mitochondrial dysfunction to stimulate tumor-specific immunological response for enhanced mild-temperature photothermal efficacy.
Zhou Z; Jiang N; Chen J; Zheng C; Guo Y; Ye R; Qi R; Shen J
J Nanobiotechnology; 2021 Nov; 19(1):375. PubMed ID: 34794446
[TBL] [Abstract][Full Text] [Related]
58. Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas.
Yang MW; Fu XL; Jiang YS; Chen XJ; Tao LY; Yang JY; Huo YM; Liu W; Zhang JF; Liu PF; Liu Q; Hua R; Zhang ZG; Sun YW; Liu DJ
World J Gastroenterol; 2019 Apr; 25(14):1684-1696. PubMed ID: 31011254
[TBL] [Abstract][Full Text] [Related]
59. Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses.
Liu B; Guo H; Xu J; Qin T; Guo Q; Gu N; Zhang D; Qian W; Dai J; Hou S; Wang H; Guo Y
MAbs; 2018; 10(2):315-324. PubMed ID: 29182441
[TBL] [Abstract][Full Text] [Related]
60. MMP-2 Responsive Peptide Hydrogel-Based Nanoplatform for Multimodal Tumor Therapy.
Zhang Q; Hu W; Guo M; Zhang X; Zhang Q; Peng F; Yan L; Hu Z; Tangthianchaichana J; Shen Y; Hu H; Du S; Lu Y
Int J Nanomedicine; 2024; 19():53-71. PubMed ID: 38187906
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]